# Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

> **NCT03241446** · PHASE1 · WITHDRAWN · sponsor: **Navidea Biopharmaceuticals**

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Tilmanocept

## Key facts

- **NCT ID:** NCT03241446
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09
- **Primary completion:** 2018-01
- **Final completion:** 2018-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was combined with another trial that was on-going.
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241446, "Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03241446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*